REYON Pharmaceutical Co., Ltd. (KRX:102460)
South Korea · Delayed Price · Currency is KRW 11,100
+40 (0.36%)
Last updated: Apr 24, 2026, 3:00 PM KST
REYON Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 145,929 | 148,300 | 151,071 | 154,039 | 142,801 |
Other Revenue | -0 | -0 | -0 | - | - |
| 145,929 | 148,300 | 151,071 | 154,039 | 142,801 | |
Revenue Growth (YoY) | -1.60% | -1.84% | -1.93% | 7.87% | 9.82% |
Cost of Revenue | 108,685 | 76,615 | 73,347 | 73,475 | 64,348 |
Gross Profit | 37,244 | 71,685 | 77,724 | 80,564 | 78,453 |
Selling, General & Admin | 59,220 | 64,138 | 64,306 | 66,286 | 63,151 |
Research & Development | 3,906 | 3,318 | 8,375 | 6,705 | 9,725 |
Amortization of Goodwill & Intangibles | 4.65 | 6.59 | 12.09 | 20.48 | 32.68 |
Other Operating Expenses | 973.37 | 1,046 | 981.05 | 942.46 | 958.94 |
Operating Expenses | 68,806 | 72,670 | 75,951 | 76,116 | 76,909 |
Operating Income | -31,562 | -985.46 | 1,773 | 4,448 | 1,545 |
Interest Expense | -13,211 | -1,253 | -195.53 | -122.2 | -111.19 |
Interest & Investment Income | 231.71 | 395.9 | 802.87 | 994.76 | 527.96 |
Earnings From Equity Investments | 1,688 | -4,359 | -960.18 | -1,968 | 1,684 |
Currency Exchange Gain (Loss) | -20.3 | 72.68 | 124.67 | -91.55 | 12.43 |
Other Non Operating Income (Expenses) | 17,323 | 11,217 | 4,938 | -945.79 | 514.97 |
EBT Excluding Unusual Items | -25,551 | 5,088 | 6,483 | 2,315 | 4,173 |
Gain (Loss) on Sale of Investments | 672.66 | 24.58 | -3,183 | 4,262 | 1,125 |
Gain (Loss) on Sale of Assets | 261.4 | 323.88 | 732.32 | 317.22 | 547.04 |
Other Unusual Items | - | -273.27 | - | - | - |
Pretax Income | -24,616 | 5,163 | 4,032 | 6,894 | 5,845 |
Income Tax Expense | 5,017 | 1,012 | 448.59 | -539.77 | 307.51 |
Earnings From Continuing Operations | -29,633 | 4,151 | 3,583 | 7,434 | 5,537 |
Net Income | -29,633 | 4,151 | 3,583 | 7,434 | 5,537 |
Preferred Dividends & Other Adjustments | - | - | - | 75 | 125 |
Net Income to Common | -29,633 | 4,151 | 3,583 | 7,359 | 5,412 |
Net Income Growth | - | 15.85% | -51.80% | 34.25% | 44.03% |
Shares Outstanding (Basic) | 18 | 18 | 18 | 18 | 18 |
Shares Outstanding (Diluted) | 18 | 18 | 18 | 18 | 18 |
Shares Change (YoY) | -0.17% | 0.15% | 0.46% | 3.03% | 4.05% |
EPS (Basic) | -1616.00 | 226.00 | 195.38 | 414.51 | 305.44 |
EPS (Diluted) | -1616.00 | 226.00 | 195.00 | 407.18 | 305.00 |
EPS Growth | - | 15.90% | -52.11% | 33.50% | 35.10% |
Free Cash Flow | -6,459 | -17,448 | -20,225 | -54,404 | -105,293 |
Free Cash Flow Per Share | -352.23 | -949.87 | -1102.71 | -2979.96 | -5942.30 |
Dividend Per Share | - | - | 150.000 | 150.000 | 250.000 |
Dividend Growth | - | - | - | -40.00% | 25.00% |
Gross Margin | 25.52% | 48.34% | 51.45% | 52.30% | 54.94% |
Operating Margin | -21.63% | -0.66% | 1.17% | 2.89% | 1.08% |
Profit Margin | -20.31% | 2.80% | 2.37% | 4.78% | 3.79% |
Free Cash Flow Margin | -4.43% | -11.77% | -13.39% | -35.32% | -73.73% |
EBITDA | 232.35 | 5,358 | 6,555 | 8,981 | 6,210 |
EBITDA Margin | 0.16% | 3.61% | 4.34% | 5.83% | 4.35% |
D&A For EBITDA | 31,794 | 6,344 | 4,782 | 4,534 | 4,666 |
EBIT | -31,562 | -985.46 | 1,773 | 4,448 | 1,545 |
EBIT Margin | -21.63% | -0.66% | 1.17% | 2.89% | 1.08% |
Effective Tax Rate | - | 19.60% | 11.13% | - | 5.26% |
Advertising Expenses | 108.11 | 81.74 | 76.91 | 106.09 | 56.01 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.